| Notes |
- Drug used in the treatment of HIV infections. (B574.69.w69)
- Intracellularly phosphorylated to 2',3'dideoxyadenosine (ddA) 5'-triphosphate,
then incorporated by HIV-RT, with removal of the diphosphate group,
into the viral DNA, acting as a chain terminator. (J549.30.w1)
- A purine analogue. Use has
been limited due to gastrointestinal discomfort which may occur
when the oral formulation is used. (B574.69.w69)
- Active against HIV-1 and HIV-2. (J549.30.w1)
- Used particularly in advanced disease, in combination with
other agents. (J549.30.w1)
- Orally 400 mg/day as two 100 mg tablets twice daily or two
200 mg tablets once daily. (J549.30.w1)
|
